CIC
MRSN

Cornercap Investment Counsel’s Mersana Therapeutics MRSN Stock Holding History

Cornercap Investment Counsel’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,705
Closed -$175K – 632
2023
Q1 		$175K Hold
1,705
– – 0.03% 512
2022
Q4 		$250K Hold
1,705
– – 0.04% 487
2022
Q3 		$288K Buy
1,705
+86
+5% +$14K 0.05% 456
2022
Q2 		$187K Buy
+1,619
New +$152K 0.03% 492

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Cornercap Investment Counsel's MRSN Position: Q2 2023 in Review

Cornercap Investment Counsel sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 1,705 shares — an estimated $175K sold.

Cornercap Investment Counsel first reported a position in MRSN in Q2 2022 and held it in 4 quarters. The position peaked at $288K in Q3 2022. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Cornercap Investment Counsel reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cornercap Investment Counsel sold 1,705 Mersana Therapeutics shares in Q2 2023, an estimated $175K.
  • Cornercap Investment Counsel first reported a position in Mersana Therapeutics in Q2 2022 and held it in 4 quarters.
  • Cornercap Investment Counsel's Mersana Therapeutics position peaked at $288K in Q3 2022.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Cornercap Investment Counsel's 13F filing for Q2 2023, filed 11 Aug 2023.